This article was originally published in The Gray Sheet
Rapid HIV diagnostic test will be marketed worldwide under an exclusive agreement with the German-American Institute for Applied Biomedical Research (GAIFAR), which manufactures the product. Preliminary data on the 30-minute test show "100% accuracy" in specificity and sensitivity, Bico says. The firm also acquired rights to the InstantConfirm Western-Blot confirmatory HIV rapid test and InstantDifferentiate rapid test for detecting the difference between HIV-1 and HIV-2. Bico plans initially to target overseas markets; GAIFAR will pursue FDA approval "immediately" for sales in the U.S
You may also be interested in...
The national regulator is to undergo a review in 2021 as the UK begins life as a former EU member, presenting opportunities to be seized.
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.